During a recent reunion of immediate family members in North Carolina, we received devastating news that a nephew out in California, a husband and father of three, had just been diagnosed with a glioblastoma, one of the most horrifically aggressive types of cancer.
Back in North Carolina, the reunion group included a nursing administrator, an MD specializing in genetics, a computer scientist expert in AI and ML, two bio-pharma research chemists – one an expert in CAD tools for protein synthesis and the other with expertise in targeted chemo therapies for oncology – as well as a couple of electrical engineers thrown in for good measure.
In other words, it was a custom-built conference for discussing cell physiology, brain function, clinical protocols, targeted therapies, genetic mutation, and the emerging science and software of semiconductor-based artificial intelligence and neuromorphic computing.
What the conference attendees wanted was to give hope to the nephew in California, despite the brutal reality of the current state of the art of treatments for virulently malignant brain tumors. However, after many hours of discussion in North Carolina the group concluded that the situation in California was dire, even hopeless, given what is currently known about glioblastoma.
